Bariatric Surgery and Non-Alcoholic Fatty Liver Disease: Current and Potential Future Treatments

Patel, 2009, Effect of weight loss on nonalcoholic fatty liver disease, J Clin Gastroenterol, 43, 970, 10.1097/MCG.0b013e3181b57475

Kopelman, 2000, Obesity as a medical problem, Nature, 404, 635, 10.1038/35007508

Younossi, 2014, Systematic review with meta-analysis: non-alcoholic steatohepatitis – a case for personalized treatment based on pathogenic targets, Aliment Pharmacol Ther, 39, 3, 10.1111/apt.12543

Paredes, 2012, Nonalcoholic fatty liver disease, Clin Liver Dis, 16, 397, 10.1016/j.cld.2012.03.005

Chalasani, 2012, The diagnosis and managements of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association, Hepatology, 55, 2005, 10.1002/hep.25762

Karlas, 2013, Gastrointestinal complications of obesity: non-alcholic fatty liver disease (NAFLD) and its sequelae, Best Pract Res Clin Endocrinol Metab, 27, 195, 10.1016/j.beem.2013.02.002

Attar, 2013, Current concepts and management approaches in nonalcoholic fatty liver disease, ScientificWorldJournal, 2013, 481893, 10.1155/2013/481893

Tanaka, 2011, Clinical characteristics of de novo nonalcoholic fatty liver disease following pancreaticoduodenectomy, J Gastroenterol, 46, 758, 10.1007/s00535-011-0370-5

Marra, 2013, Pathophysiology of NASH: perspectives for a targeted treatment, Curr Pharm Des, 19, 5250, 10.2174/13816128113199990344

Franz, 2007, Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up, J Am Diet Assoc, 107, 1755, 10.1016/j.jada.2007.07.017

Hafeez, 2013, Bariatric surgery as potential treatment for nonalcoholic fatty liver disease: a future treatment by choice or by chance?, J Obes, 2013, 839275, 10.1155/2013/839275

Lingvay, 2007, Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes, J Diabetes Complications, 21, 137, 10.1016/j.jdiacomp.2007.02.005

Bellentani, 2010, Epidemiology of non-alcoholic fatty liver disease, Dig Dis, 28, 155, 10.1159/000282080

Hussein, 2007, Orlostat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH), Dig Dis Sci, 52, 2512, 10.1007/s10620-006-9631-1

Harrison, 2009, Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial, Hepatology, 49, 80, 10.1002/hep.22575

Drucker, 2006, The biology of incretin hormones, Cell Metab, 3, 153, 10.1016/j.cmet.2006.01.004

Ding, 2006, Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice, Hepatology, 43, 173, 10.1002/hep.21006

Trevaskis, 2012, Glucagon-like protein-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice, Am J Physiol Gastrointest Liver Physiol, 302, G762, 10.1152/ajpgi.00476.2011

Kim, 2012, When GLP-1 hits the liver: a novel approach for insulin resistance and NASH, Am J Physiol Gastrointest Liver Physiol, 302, G759, 10.1152/ajpgi.00078.2012

Visbøll, 2012, Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta- analysis of randomized controlled trials, BMJ, 344, d7771, 10.1136/bmj.d7771

Astrup, 2009, Effects of liraglutide in the treatment of obesity: a randomized, double-blind, placebo-controlled study, Lancet, 374, 1600, 10.1016/S0140-6736(09)61375-1

Mummadi, 2008, Effects of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta- analysis, Clin Gastroenterol Hepatol, 6, 1396, 10.1016/j.cgh.2008.08.012

Chavez-Tapia, 2010, Bariatric surgery for non-alcoholic steatohepatitis in obese patients, Cochrane Detabase Syst Rev, 20, CD007340, 10.1002/14651858.CD007340.pub2

Knop, 2009, Resolution of type 2 diabetes following gastric bypass surgery: involvement of gut-derived glucagon and glucagonotropic signalling?, Diabetologia, 52, 2270, 10.1007/s00125-009-1511-8

Sasaki, 2014, Current status of bariatric surgery in Japan and effectiveness in obesity and diabetes, J Gastroenterol, 49, 57, 10.1007/s00535-013-0802-5

Mells, 2013, The role of gastrointestinal hormones in hepatic lipid metabolism, Semin Liver Dis, 33, 343, 10.1055/s-0033-1358527

Falken, 2011, Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides, J Clin Endocrinol Metab, 96, 2227, 10.1210/jc.2010-2876

Barker, 2006, Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery, Am J Gastroenterol, 101, 368, 10.1111/j.1572-0241.2006.00419.x

Tiikkainen, 2003, Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content, Diabetes, 52, 701, 10.2337/diabetes.52.3.701

Silverman, 1995, Regression of hepatic steatosis in morbidly obese persons after gastric bypass, Am J Clin Pathol, 104, 23, 10.1093/ajcp/104.1.23

Mattar, 2005, Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome, Ann Surg, 242, 610, 10.1097/01.sla.0000179652.07502.3f

Clark, 2005, Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease, Obes Surg, 13, 1180

Mottin, 2005, Histological behavior of hepatic steatosis in morbidly obese patients after weight loss induced by bariatric surgery, Obes Surg, 15, 788, 10.1381/0960892054222830

Klein, 2006, Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease, Gastroenterology, 130, 1564, 10.1053/j.gastro.2006.01.042

Csendes, 2006, Histological findings in the liver before and after gastric bypass, Obes Surg, 16, 607, 10.1381/096089206776944904

de Almeida, 2006, Roux-en-Y gastric bypass improves the nonalcoholic steatohepatitis (NASH) of morbid obesity, Obes Surg, 16, 270, 10.1381/096089206776116462

Furuya, 2007, Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years, J Gastroenterol Hepatol, 22, 510, 10.1111/j.1440-1746.2007.04833.x

Liu, 2007, Resolution of nonalcoholic steatohepatitis after gastric bypass surgery, Obes Surg, 17, 486, 10.1007/s11695-007-9086-2

Weiner, 2010, Surgical treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease, Dig Dis, 28, 274, 10.1159/000282102

Meretto, 2012, Effect of bariatric surgery on liver fibrosis, Obes Surg, 22, 1044, 10.1007/s11695-011-0559-y

Vargas, 2012, Surgically induced weight loss by gastric bypass improves non alcoholic fatty liver disease in morbid obese patients, World J Hepatol, 4, 382, 10.4254/wjh.v4.i12.382

Tai, 2012, Improvement of nonalcoholic fatty liver disease after bariatric surgery in morbidly obese Chinese patients, Obes Surg, 22, 1016, 10.1007/s11695-011-0579-7

Himpens, 2006, A prospective randomized study between laparoscopic gastric banding and laparoscopic isolated sleeve gastrectomy: results after 1 and 3 years, Obes Surg, 16, 1450, 10.1381/096089206778869933

Hutter, 2011, First report from the American College of Surgeons Bariatric Surgery Center Network: laparoscopic sleeve gastrectomy has morbidity and effectiveness positioned between the band and the bypass, Ann Surg, 254, 410, 10.1097/SLA.0b013e31822c9dac

Buckwald, 2013, Metabolic/bariatric surgery worldwide 2011, Obes Surg, 23, 427, 10.1007/s11695-012-0864-0

Dixon, 2004, Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss, Hepatology, 39, 1647, 10.1002/hep.20251

Dixon, 2006, Weight loss nad non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement, Obes Surg, 16, 1278, 10.1381/096089206778663805

Mathurin, 2009, Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease, Gastroenterology, 137, 532, 10.1053/j.gastro.2009.04.052

Karcz, 2011, Influence of sleeve gastrectomy on NASH and type 2 diabetes mellitus, J Obes, 2011, 765473, 10.1155/2011/765473

Umemura, 2014, Effects of changes in adipocyte hormones and visceral adipose tissue and the reduction of obesity-related comorbidities after laparoscopic sleeve gastrectomy in Japanese patients with severe obesity, Endocr J, 61, 381, 10.1507/endocrj.EJ13-0524

Keshishian, 2005, Duodenal switch has no detrimental effects on hepatic function and improves hepatic steatohepatitis after 6 months, Obes Surg, 15, 1418, 10.1381/096089205774859290

Kral, 2004, Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis, Surgery, 135, 48, 10.1016/j.surg.2003.10.003

Browning, 2004, Molecular mediators of hepatic steatosis and liver injury, J Clin Invest, 114, 147, 10.1172/JCI200422422

Sung, 2011, Interrelationship between fatty liver and insulin resistance in the development of type 2 diabetes, J Clin Endocrinol Metab, 96, 1093, 10.1210/jc.2010-2190

Ionut, 2013, Gastrointestinal hormones and bariatric surgery-induced weight loss, Obesity, 21, 1093, 10.1002/oby.20364

Patti, 2009, Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism, Obesity, 17, 1671, 10.1038/oby.2009.102

Haluzíková, 2013, Laparoscopic sleeve gastrectomy differentially affects serum concentrations of FGF-19 and FGF-21 in morbidly obese subjects, Obesity (Silver Spring), 21, 1335, 10.1002/oby.20208

Pournaras, 2012, The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control, Endocrinology, 153, 3613, 10.1210/en.2011-2145

Vest, 2012, Bariatric surgery and cardiovascular outcomes: a systematic review, Heart, 98, 1763, 10.1136/heartjnl-2012-301778

Poirier, 2014, Role of bariatric surgery in diabetes, Curr Cardiol Rep, 16, 444, 10.1007/s11886-013-0444-5

Laferrere, 2011, Diabetes remission after bariatric surgery: is it just the incretins?, Int J Obes (Lond), 35, S22, 10.1038/ijo.2011.143